1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- Good adherence to adjuvant endocrine therapy in early breast cancer – a population-based study based on the Swedish Prescribed Drug Register
- Omitting radiotherapy in women ≥ 65 years with low-risk early breast cancer after breast-conserving surgery and adjuvant endocrine therapy is safe
-
Minimizing inequality in access to precision medicine in breast cancer by real-time population-based molecular analysis in the SCAN-B initiative
Rydén, Lisa LU
;
Loman, Niklas
LU
;
Larsson, Christer
LU
;
Hegardt, Cecilia
LU
;
Vallon-Christersson, Johan
LU
;
Malmberg, Martin
;
Lindman, Henrik
;
Ehinger, Anna
LU
;
Saal, Lao H.
LU
and
Borg, Åke
LU
(2018)
In British Journal of Surgery
105(2).
p.158-168
Mark
- 2017
- Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
- Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
- 2016
- Årsrapport 2015 från Nationella Bröstcancerregistret
- 2013
- Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study
- Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
- 2011
- A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer